Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.
ARNI
Sacubitril/valsartan
chemotherapy
hairy cell leukaemia
heart failure
Journal
Clinical Medicine Insights. Cardiology
ISSN: 1179-5468
Titre abrégé: Clin Med Insights Cardiol
Pays: United States
ID NLM: 101525768
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
08
2020
accepted:
12
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Experience with angiotensin-receptor neprilysin inhibitors (ARNI) in oncologic patients with heart failure (HF) is limited. We report a case of ARNI started as first-choice therapy in a patient with relapsing hairy cell leukaemia (HCL) and HF with depressed left ventricular ejection fraction (LVEF). A middle-aged male, previously treated with rituximab for HCL, was scheduled for cardiologic screening before starting a new antineoplastic therapy for cancer relapse. The patient had symptomatic HF with reduced LVEF and high NT-proBNP levels. In this patient, early ARNI treatment was well tolerated and produced a rapid and durable improvement of symptoms, LVEF and NT-proBNP levels. Consequently, the oncologic team could start an experimental treatment with obinutuzumab, with complete HCL remission. In conclusion, in this patient with HCL and HF, ARNI therapy was safe and effective, contributing to undelayed cancer treatment.
Identifiants
pubmed: 33911910
doi: 10.1177/11795468211010706
pii: 10.1177_11795468211010706
pmc: PMC8050758
doi:
Types de publication
Case Reports
Langues
eng
Pagination
11795468211010706Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Dr Alessandro Lupi received speaker honoraria from the drug company Novartis. All other authors declare no conflict of interest.
Références
Pharmacol Res. 2020 Jan;151:104577
pubmed: 31790821
Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):268-269
pubmed: 31416729
SAGE Open Med Case Rep. 2020 Sep 15;8:2050313X20952189
pubmed: 32974024
N Engl J Med. 2019 Feb 7;380(6):539-548
pubmed: 30415601
JAMA. 2019 Sep 2;:1-11
pubmed: 31475295
Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36
pubmed: 21635149
Cardiology. 2006;105(3):184-7
pubmed: 16490965
Eur J Heart Fail. 2019 Aug;21(8):998-1007
pubmed: 31134724
J Oncol Pharm Pract. 2019 Jul;25(5):1231-1234
pubmed: 29945530
Curr Treat Options Cardiovasc Med. 2018 Jun 19;20(7):53
pubmed: 29922881
Int J Cardiol Heart Vasc. 2020 Oct 22;31:100656
pubmed: 33134479
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Int J Cardiol Heart Vasc. 2019 Sep 03;25:100418
pubmed: 31517034
Circ Cardiovasc Imaging. 2016 Aug;9(8):
pubmed: 27502058
Breast Cancer Res Treat. 2019 Jun;175(3):595-603
pubmed: 30852761
ESC Heart Fail. 2020 Apr;7(2):763-767
pubmed: 32022485
JACC Cardiovasc Imaging. 2018 Aug;11(8):1045-1055
pubmed: 30092965
Eur Heart J Cardiovasc Pharmacother. 2020 Oct 29;:
pubmed: 33119090
Leuk Lymphoma. 2015 Mar;56(3):805-7
pubmed: 24913498
Am J Nephrol. 2011;33(2):121-30
pubmed: 21242672